Pharma-Bio Serv (PBSV) Receivables - Net (2010 - 2026)

Pharma-Bio Serv (PBSV) has 17 years of Receivables - Net data on file, last reported at $2.7 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Net fell 49.91% year-over-year to $2.7 million; the trailing twelve-month figure through Jan 2026 stood at $2.7 million (down 49.91% YoY), and the FY2025 full-year result was $5.3 million, changed 0.0% from the prior year.
• Receivables - Net for Q1 2026 stood at $2.7 million, up from $2.4 million in the prior quarter.
• Across five years, Receivables - Net topped out at $5.5 million in Q2 2022 and bottomed at $2.0 million in Q3 2025.
• The 5-year median for Receivables - Net is $4.8 million (2022), against an average of $4.2 million.
• The widest annual swing landed in 2022, when Receivables - Net soared 858.17%; it then plunged 61.97% in 2025.
• A 5-year view of Receivables - Net shows it stood at $5.0 million in 2022, then declined by 20.91% to $3.9 million in 2023, then plunged by 36.29% to $2.5 million in 2024, then declined by 5.98% to $2.4 million in 2025, then gained by 12.45% to $2.7 million in 2026.
• The last three Receivables - Net figures came in at $2.7 million (Q1 2026), $2.4 million (Q4 2025), and $2.0 million (Q3 2025), per Business Quant data.

Peer Comparison